Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10

Immunological Investigations

Volumn 37, Issue 4, 2008, Pages 315-338

  Dobrzanski, Mark J ^a   Reome, Joyce B ^b   Hylind, James C ^b   Rewers Felkins, Kathleen A ^a   Abdulsamad, Khaliquzzaman ^a   Adams, Shawna L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TRUDEAU INSTITUTE   (United States)

Author keywords

Chemotherapy; Cytokines; IL 10; Immunoregulatory cells; T effector memory cells; Tc1 Th1 cells; Tumor immunity

Indexed keywords

ALPHA2 INTEGRIN; CD3 ANTIGEN; CD8 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 10; METHOTREXATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; INTEGRIN ALPHA2; INTERLEUKIN-10; MAMMARY NEOPLASMS, ANIMAL; METHOTREXATE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 45949109157     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130802083762     Document Type: Article

References (68)

1. Almeida, A. R. M., Rocha, B., Freitas, A. A., Tanchot, C. (2005). Homeostasis of T cell numbers: from thymus production to peripheral compartmentalization and the indexation of regulatory T cells. Sem. Immunol. 17:239-249.
2. Arase, H., Saito, T., Phillips, J. H., Lanier, L. L. (2001). Cutting Edge: The mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha2 Integrin, very late antigen-2). J. Immunol. 167:1141-1144.
3. Awwad, M., North, R. J. (1988). Cyclophosphamide (CY)-facilitated adoptive immunotherapy of a CY- resistant tumor. Evidence that CY permits the expression of adoptive T cell-mediated immunity by removing suppressor T cells rather than by reducing tumor burden. Immunology 65:87-92.
4. Barrat, F. J., Cua, D. J., Boonstra, A., Richards, D. F., Crain, C., Savelkoul, H. F., de Waal-Malefyt, R., Coffman, R. L., Hawrylowicz, C. M., O'Garra, A. (2002). In vitro generation of IL-10-producing regulatory CD4 T cells is induced by immunosuppressive drugs and inhibited by Th1 and Th2-inducing cytokines. J. Exp. Med. 195:603-615.
5. Bishop, M. R., Fowler, D. H., Marchigiani, D., Castro, K., Kasten-Sportes, C., Steinberg, S. M., Gea-Banacloche, J. C., Dean, R., Chow, C. H., Carter, C., Read, E. J., Leitman, S., Gress, R. (2004). Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J. Clin. Oncol. 22:3886-3894.
6. Carter, L. L., Dutton, R. W. (1995). Cutting edge: Relative perforin and Fas-mediated lysis in T1 and T2 CD8 effector populations. J. Immunol. 155:1028-1031.
7. Casares, N., Pequignot, M. O., et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202:1691-1701.
8. Cerwenka, A., Morgan, T. M., Dutton, R. W. (1999). Naïve, effector and memory CD8 T cells in protection against pulmonary influenza virus infection: Homing properties rather than initial frequencies are crucial. J. Immunol. 163:5535-5543.
9. Chabner, B. A., Roberts, Jr., T. G. (2005). Chemotherapy and the war on cancer. Nat. Rev. Cancer 5:65-72.
10. Charbonnier, L. M., van Duivenvoorde, L. M., Apparailly, F., Cantos, C., Han, W. G. H., Noel, D., Duperray, C., Huizinga, T. W. J., Toes, R. E. M., Jorgensen, C., Louis-Plence, P. (2006). Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b regulatory T cells. J. Immunol. 177:3806-3813.
11. Chess, L., Jiang, H. (2004). Resurrecting CD8 suppressor T cells. Nature Immunol. 5:469-349.
12. Croft, M., Carter, L. L., Swain, S. L. Dutton, R. W. (1994). Generation of polarized antigen specific CD8 effector populations: Reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715-1794.
13. Crowe, N. Y., Coquet, J. M., Berzins, S. P., Kyparissoudis, K., Keating, R., Pellicci, D. G., Hayakawa, Y., Godfrey, D. I., Smyth, M. J. (2005). Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Expt. Med. 202:1279-1288.
14. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burrow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, B., Myers, L., Luckner, A., Disis, M. L., Knutson, K. L., Chen, L., Zou, W. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
15. Dobrzanski, M. J., Reome, J. B., Dutton, R. W. (2000). Type 1 and type 2 CD8 effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumors. J. Immunol. 164:916-925.
16. Dobrzanski, M. J., Reome, J. B., Hollenbaugh, J. A., Dutton, R. W. (2004a). Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous Type 1 antitumor responses. J. Immunol. 172:1380-1391.
17. Dobrzanski, M. J., Reome, J. B., Hylind, J. C., Rewers-Felkins, K. A. (2006). CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation and function in progressive breast cancer. J. Immunol. 177:8191-8201.
18. Dobrzanski, M. J., Reome, J. B., Hollenbaugh, J. A., Hylind, J. C., Dutton, R. W. (2004b). Effector cell-derived lymphotoxin-? and FasL, but not perforin, promote Tc1 and Tc2 effector cell-mediated Tumor Therapy in established pulmonary metastases. Cancer Res. 64:406-413.
19. Dudley, M. E., Wunderlich, J. R., Robbins, J. R., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., Robinson, M. R., Raffeld, M., Duray, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., Mavroukakis, S. A., White, D. E., Rosenberg, S. A. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854.
20. Eberl, G., Lees, R., Smiley, S. T., Taniguchi, M., Grusby, M. J., MacDonald, H. R. (1999). Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J. Immunol. 162:6410-6419.
21. Endharti, A. T., Rifa'I, M., Shi, Z., Fukuoka, Y., Nakahara, Y., Kawamoto, Y., Takeda, K., Isobe, K., Suzuki, H. (2005). Cutting Edge: CD8 CD122 regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8 T cells. J. Immunol. 175:7093-7097.
22. Garrod, K. R., Wei, S. H., Parker, I., Cahalan, M. D. (2007). Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-matched targets. PNAS 104:12081-12086.
23. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J., Van Kaer, L. (2004). NKT cells: what's in a name? Nat. Rev. Immunol. 4:231-237.
24. Gonzalez, A., Andre-Schmutz, I., Carnaud, C., Mathis, D., Benoist, C. (2001). Damage control, rather than unresponsiveness, effected by protective DX5 T cells in autoimmune diabetes. Nat. Immunol. 2:1117-1125.
25. Groux, H., O'Garra, A., Bigler, M., Rouleau, M., de Vries, J., Roncarolo, M. G. (1997). Generation of a novel regulatory CD4 T cell population which inhibits antigen-specific T cell responses. Nature 389:737-742.
26. Hammond, K. J. L., Pelikan, S. B., Crowe, N. Y., Randle-Barrett, E., Nakayama, T., Taniguchi, M., Smyth, M. J., van Driel, I. R., Scollay, R., Baxter, A. G., Godfrey, D. I. (1999). NKT cells are phenotypically and functionally diverse. Eur. J. Immunol. 29:3768-3781.
27. Jiang, H., Chess, L. (2006). Regulation of immune responses by T cells. N. Engl J. Med. 354: 1166-1176.
28. Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J., Chabner, B. A. (1983). The pharmacological and clinical use of methotrexate. N. Engl. J. Med. 309:1094-1104.
29. Joyee, A. G., Qiu, H., Wang, S., Fan, Y., Bilenki, L., Yang, X. (2007). Distinct NKT cell subsets are induced by different Chlamydia species leading to differential adaptive immunity and host resistance to the infections. J. Immunol. 178:1048-1058.
30. Juliano, R. L., Haskill, S. (1993). Signal transduction from the extracellular matrix. J. Cell Biol. 120:577-585.
31. Kassiotis, G., Gray, D., Kiafard, Z., Zwirner, J., Stockinger, B. (2006). Functional specialization of memory Th cells revealed by expression of integrin CD49b. J. Immunol. 177:968-975.
32. Lake, R. A., Robinson, B. W. S. (2005). Immunotherapy and chemotherapy-a practical partnership. Nat Rev. Cancer 5:397-405.
33. Longley, D. B., Harkin, D. P., Johnson, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3:330-338.
34. Maggi, E., Manetti, R., Annunziato, F., Cosmi, L., Giudizi, M. G., Biagiotti, R., Galli, G., Zuccati, G., Romagnani, S. (1997). Functional characterization and modulation of cytokine production by CD8 T cells from human immunodeficiency virus-infected individuals. Blood 89:3672-3679.
35. Mainiero, F., Gismondi, A., Soriani, A., Cippitelli, M., Palmieri, G., Jacobelli, J., Piccoli, M., Frati, L., Santoni, A. (1998). Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J. Exp. Med. 188: 1267-1275.
36. Marincola, F. M., Wang, E., Herlyn, M., Seliger, B., Ferrone, S. (2003). Tumors as elusive targets of T cell- based active immunotherapy. Trends Immunol. 24:334-341.
37. Messman, R. A., Allegra, C. J. (2001). Cancer chemotherapy and biotherapy. (B. A. Chabner and D. Longo, eds.). Lippincott Williams and Wilkins: Philadelphia, PA, pp. 139-184.
38. Micheau, O., Solary, E., Hammann, A., Martin, F., Dimanche-Boitrel, M. T. (1997). Sensitization of cancer cells treated with cytoablative drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst. 89:783-786.
39. Minchinton, A. I., Tannock, I. F. (2006). Drug penetration in solid tumors. Nat. Rev. Cancer 6: 583-592.
40. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., Ochoa, A. C. (1992). Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798.
41. Moodycliffe, A. M., Ngheim, D., Clydesdale, G., Ullrich, S. E. (2000). Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol. 1:521-525.
42. Moore, K. W., de Waal Malefyt, R., Coffman, R. L., O'Garra, A. (2001). IL-10 and the IL-10 receptor. Annu. Rev. Immunol. 19:683-765.
43. Morgan, J. D., Liblau, R., Scott, B., Fleck, S., McDevitt, H. O., Sarvetnick, N., Lo, D., Sherman, L. A. (1996). CD8 T cell mediated spontaneous diabetes in neonatal mice. J. Immunol. 157:978-986.
44. Nanni, P., de Giovanni, C., Lollini, P. L., Prodi, G. (1983). TS/A: a new metastasizing cell line from BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 4:373-380.
45. North, R. J. (1985). Downregulation of the antitumor immune response. Adv. Cancer Res. 45:1-43.
46. Nowak, A. K., Robinson, B. W. S., Lake, R. A. (2003). Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63:4490-4496.
47. Pellicci, D. G., Hammond, K. J. L., Coquet, J., Kyparissoudis, K., Brooks, A. G., Kedzierska, K., Keating, R., Turner, S., Berzins, S., Smyth, M. J., Godfrey, D. I. (2005). DX5/CD49b-positive T cells are not synonymous with CD1d-dependent NKT cells. J. Immunol. 175:4416-4425.
48. Piccirillo, C. A., Shevach, E. M. (2004). Naturally occurring CD4/CD25 immunoregulatory T cells: central players in the arena of peripheral tolerance. Sem Immunol. 16:81-88.
49. Rahmoun, M., Foussat, A., Groux, H., Pene, J., Yssel, H., Chanez, P. (2006). Enhanced frequency of CD18- and CD49b-expressing T cells in peripheral blood of asthmatic patients correlates with disease severity. Int. Arch. Allergy Immunol. 140:139-149.
50. Restifo, N. P. (2000). Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol. 12:597-603.
51. Rosenberg, S. A. (2004). Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350:1461-1465.
52. Sad, S., Marcotte, R., Mosmann, T. R. (1995). Cytokine induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting th1 or th2 cytokines. Immunity 2:271-280.
53. Salgame, P., Abrams, J. S., Clayberger, C., Goldstein, H., Convit, J., Modlin, R. L., Bloom, B. (1991). Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279-283.
54. Scheffer, S. R., Nave, H., Korangy, F., et al. (2003). Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J. Cancer 103:205-211.
55. Schwartz, M. A., Schaller, M. D., Ginsberg, M. H. (1995). Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol. 11:549-599.
56. Sheu, B., Lin, R., Lien, H., Ho, H., Hsu, S., Huang, S. (2001). Predominant Th2/Tc2 polarity of tumor infiltrating lymphocytes in human cervical cancer. J. Immunol. 167:2972-2982.
57. Shi, Y., Evans, J. E., Rock, K. L. (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516-521.
58. Singh, S., Ross, S. R., Acena, M., Rowley, D. A., Schreiber, H. (1992). Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:139-146.
59. Smyth, M. J., Hayakawa, Y., Tqakeda, Y., Yagita, H. (2002). New aspects of natural-killer cell surveillance and therapy of cancer. Nat. Rev. Cancer 2:850-861.
60. Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., Hayakawa, Y. (2006). CD4 CD25 T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176:1582-1587.
61. Surh, C. D., Sprent, J. (2005). Regulation of mature T cell homeostasis. Sem. Immunol. 17:183-191.
62. Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Menard, C., Ghiringhelli, F., Terme, M., Carpentier, A. F., Darrasse-Jese, G., Lemonnier, F., Zitvogel, L. (2006). Chemotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176:2722-2729.
63. Vieira, P. L., Christensen, J. R., Minaee, S., O'Neil, E. J., Barrat, F. J., Boonstra, A., Barthlott, T., Stockinger, B., Wraith, D. C., O'Garra, A. (2004). IL-10 secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4 CD25 regulatory T cells. J. Immunol. 172:5986-5993.
64. Vukmanovic-Stejic, M., Vyas, B., Gorak-Stolinska, P., Noble, A., Kemeny, D. M. (2000). Human Tc1 and Tc2/Tc0 CD8 T cell clones display distinct cell surface and functional phenotypes. Blood 95:231-237.
65. Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., June, C. H. (2001). Regulatory CD4CD25 T cells in tumors from patients with early stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res. 61:4766-4774.
66. Yee, C., Thompson, J. A., Bryd, D., Ridell, S. R., Roche, P., Celis, E., Greenberg, P. D. (2002). Adoptive T cell therapy using antigen-specific CD8 T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. 99:16168-16176.
67. Yee, C., Thompson, J. A., Roche, P., Bryd, D. R., Lee, P. P., Piepkorn, M., Kenyon, K., Davis, M. M., Riddell, S. R., Greenberg, P. D. (2000). Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192:1637-1643.
68. Zhang, C., Zhang, J., Tian, Z. (2006). The regulatory effects of natural killer cells: Do NK-reg cells" exist. Cell. Mol. Immunol. 3:241-254.